Abstract
Plasmalogen-selective phospholipase A2 (PlsEtn-PLA2) has been purified from pig brain using multiple column chromatographic procedure. The purified enzyme migrates as a single band on polyacrylamide. It is stimulated by Triton X-100 and inhibited by sodium deoxycholate. Purified PlsEtn-PLA2 is inhibited by iodoacetate, and this inhibition can be prevented by β-meracaptoethanol. Treatment of neuronal cell cultures with kainic acid stimulates PlsEtn-PLA2 activity in a dose-dependent manner, and this stimulation can be blocked by Ly294486, a selective kainic acid receptor antagonist. Activities of PlsEtn-PLA2 are markedly increased in plasma membrane and synaptosomal plasma membrane fraction prepared from nucleus basalis and hippocampal region of brains from Alzheimer disease patients compared to age-matched controls. It is proposed that accumulation of ceramide and increased expression of cytokines may be responsible for the stimulation of PlsEtn-PLA2 in Alzheimer disease.
Similar content being viewed by others
References
Farooqui AA, Ong WY, Horrocks LA, Farooqui T (2000) Brain cytosolic phospholipase A2: localization, role, and involvement in neurological diseases. Neuroscientist 6:169–180
Sun GY, Xu J, Jensen MD, Simonyi A (2004) Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 45:205–213
Phillis JW, O'Regan MH (2004) A potentially critical role of phospholipases in central nervous system ischemic, traumatic, and neurodegenerative disorders. Brain Res Brain Res Rev 44:13–47
Farooqui AA, Ong WY, Horrocks LA (2006) Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacol Rev 58:591–620
Green JT, Orr SK, Bazinet RP (2008) The emerging role of group VI calcium-independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. J Lipid Res 49:939–944
Farooqui AA, Horrocks LA (2001) Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7:232–245
Hirashima Y, Farooqui AA, Mills JS, Horrocks LA (1992) Identification and purification of calcium-independent phospholipase A2 from bovine brain cytosol. J Neurochem 59:708–714
Yang H-C, Farooqui AA, Horrocks LA (1994) Effects of sialic acid and sialoglycoconjugates on cytosolic phospholipases A2 from bovine brain. Biochem Biophys Res Commun 199:1158–1166
Farooqui AA, Yang H-C, Horrocks LA (1995) Plasmalogens, phospholipases A2 and signal transduction. Brain Res Brain Res Rev 21:152–161
Farooqui AA, Farooqui T, Horrocks LA (2008) Metabolism and functions of bioactive ether lipids. Springer, New York
Bazan NG (2005) Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 15:159–166
Bazan NG (2009) Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J Lipid Res 50:S400–S405
Latorre E, Collado MP, Fernández I, Aragonés MD, Catalán RE (2003) Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 270:36–46
Han X, Holtzman D, Mckeet DW Jr, Kelley J, Morris JC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82:809–818
Han X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2:65–77
Farooqui AA (2009) Beneficial effects of fish oil on human brain. Springer, New York
Wells K, Farooqui AA, Liss L, Horrocks LA (1995) Neural membrane phospholipids in Alzheimer disease. Neurochem Res 20:1329–1333
Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ (2001) Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26:771–782
Han X, Holtzman DM, McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77:1168–1180
Guan ZZ, Wang YA, Cairns NJ, Lantos PL, Dallner G, Sindelar PJ (1999) Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J Neuropathol Exp Neurol 58:740–747
Ginsberg L, Xuereb JH, Gershfeld NL (1998) Membrane instability, plasmalogen content, and Alzheimer's disease. J Neurochem 70:2533–2538
Périchon R, Moser AB, Wallace WC, Cunningham SC, Roth GS, Moser HW (1998) Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Biochem Biophys Res Commun 248:57–61
Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L (2003) Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 44:182–192
Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL (2007) Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48:2485–2498
Gorgas K, Teigler A, Komljenovic D, Just WW (2006) The ether lipid-deficient mouse: tracking down plasmalogen functions. Biochim Biophys Acta 1763:1511–1526
Farooqui AA, Ong WY, Lu XR, Halliwell B, Horrocks LA (2001) Neurochemical consequences of kainate-induced toxicity in brain: involvement of arachidonic acid release and prevention of toxicity by phospholipase A2 inhibitors. Brain Res Brain Res Rev 38:61–78
Farooqui AA (2009) Hot topics in neural membrane lipidology. Springer, New York
Engelmann B, Bräutigam C, Thiery J (1994) Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochem Biophys Res Commun 204:1235–1242
Maeba R, Ueta N (2004) A novel antioxidant action of ethanolamine plasmalogens in lowering the oxidizability of membranes. Biochem Soc Trans 32:141–143
Zommara M, Tachibana N, Mitsui K, Nakatani N, Sakono M, Ikeda I, Imaizumi K (1995) Inhibitory effect of ethanolamine plasmalogen on iron- and copper-dependent lipid peroxidation. Free Radic Biol Med 18:599–602
Lessig J, Fuchs B (2009) Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr Med Chem 16:2021–2041
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Farooqui, A.A. Studies on Plasmalogen-Selective Phospholipase A2 in Brain. Mol Neurobiol 41, 267–273 (2010). https://doi.org/10.1007/s12035-009-8091-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-009-8091-y